MFW
NBIX icon

Meristem Family Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Meristem Family Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,945
Closed -$384K – 331
2021
Q1 		$384K Hold
3,945
– – 0.08% 153
2020
Q4 		$378K Buy
+3,945
New +$381K 0.08% 147

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return

Meristem Family Wealth's NBIX Position: Q2 2021 in Review

Meristem Family Wealth sold out of Neurocrine Biosciences (NBIX) in Q2 2021, closing a stake of 3,945 shares — an estimated $384K sold.

Meristem Family Wealth first reported a position in NBIX in Q4 2020 and held it in 2 quarters. The position peaked at $384K in Q1 2021. 409 funds tracked by Wall St. Rank hold NBIX as of Q2 2021.

  • Meristem Family Wealth reported no remaining Neurocrine Biosciences position as of Q2 2021 after selling out during the quarter.
  • Meristem Family Wealth sold 3,945 Neurocrine Biosciences shares in Q2 2021, an estimated $384K.
  • Meristem Family Wealth first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 2 quarters.
  • Meristem Family Wealth's Neurocrine Biosciences position peaked at $384K in Q1 2021.
  • 409 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2021.

Based on Meristem Family Wealth's 13F filing for Q2 2021, filed 6 Aug 2021.